Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRX to expedite clinical trials after opening state-of-the-art lab

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers
no_picture_pai.jpg
The facility was opened on time and within budget

VolitionRx Ltd (NYSEMKT:VNRX) has opened a new research and development facility in Belgium this week.

The US-listed European cancer diagnostics group said the purpose-built laboratory would enable it to increase capacity to carry out clinical trials and to expand its scientific team.

A more modern lab and a bigger lab team should lead to trials taking less time.

WATCH a video showcasing the start-of-the art lab

READ the VolitionRX investment case

"Our capacity to run large clinical trials has increased significantly with this five-fold increase in laboratory space. This will facilitate large scale manual and automated robotic testing. We will now have the ability to work on several large trials at the same time, namely: the front-line screening colorectal cancer tests and  lung, prostate and pancreatic cancer," said Dr Marielle Herzog, Research and Development Director of Volition.

Volition's Belgian arm acquired the 19,000 square foot property for €1.2mln – about US$1.29mln.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

View full VNRX profile View Profile

VolitionRx Timeline

Newswire
September 14 2017

Related Articles

scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 12 2017
Richard Lipscombe talked revenue generation and growth path with investors.
boy leaning against chain link fence
September 14 2017
We take a look back at the progress made by Summit in the five years since we first spoke to chief executive Glyn Edwards

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use